Anti-alpha-enolase antibodies in Behcet's disease: a marker of mucocutaneous and articular disease activity?
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
CLINICAL & EXPER RHEUMATOLOGY
Citação
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, v.36, n.6, suppl.115, p.S28-S32, 2018
Resumo
Objective. To assess IgM anti-alphaenolase antibodies (AAEA) in systemic Behget's disease (BD) and its possible association with clinical manifestations and disease activity. Methods. Ninety-seven consecutively selected BD patients were compared to 36 enteropathic spondyloarthritis (ESpA) [24 Crohn's disease (CD) and 12 ulcerative colitis (UC)] patients and 87 healthy controls. 1gM AAEA was detected by immunoblotting. Disease activity was assessed by standardised indexes, Brazilian BD Current Activity Form (BR-BDCAF) for BD and HarveyBradshaw Index (HBI) for CD and UC patients. A second evaluation was performed in BD patients (n=56), regarding IgM AAEA presence, disease activity scores and C-reactive protein (CRP). Results. Higher IgM AAEA prevalence was found in 97 BD (17.7%) compared to ESpA (2.8%) and healthy controls (2.3%), p< O. O01. IgM AAEA frequency was higher in active BD compared to inactive BD (30.2% vs. 7.4%, p=O. O06), a finding confirmed in the second cross-sectional evaluation of 56 of these BD patients (45.5% vs. 13.3%, p=O. 02). Mean BR-BDCAF scores were higher in IgM AAEA positive group on both evaluations (9.1 + 5.4 vs. 4.9 + 4.9, p=O. O02; 5.0 + 4.9 vs. 2.2 + 2.9, p=O. 01, respectively). BD patients with mucocutaneous and articular symptoms presented higher IgM AAEA positivity in the first and second evaluations (64.7% vs. 27.5%, p=O. O05; 36.4% vs. 7.1%, p=0.039 respectively). Conclusions. Our data support the notion that alpha-enolase is a target antigen in BD, particularly associated with disease activity, mucocutaneous and articular involvement. In addition, IgM AAEA may distinguish BD from ESpA, especially in patients with high disease activity.
Palavras-chave
Behcet's syndrome, clinical diagnosis, disease activity marker, autoantibodies, human alpha-enolase
Referências
- AYDINTUG AO, 1993, CLIN IMMUNOL IMMUNOP, V67, P157, DOI 10.1006/clin.1993.1059
- Bayraktar Y, 2000, J CLIN GASTROENTEROL, V30, P144, DOI 10.1097/00004836-200003000-00006
- Bhakta BB, 1999, RHEUMATOLOGY, V38, P728, DOI 10.1093/rheumatology/38.8.728
- Calamia KT, 2009, ARTHRIT RHEUM-ARTHR, V61, P600, DOI 10.1002/art.24423
- Diri E, 2001, ANN RHEUM DIS, V60, P1074, DOI 10.1136/ard.60.11.1074
- DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003
- HARVEY RF, 1980, LANCET, V1, P514
- International Study Group for Beh~et's Disease, 1990, LANCET, V335, P1078, DOI 10.1016/0140-
- Lee JH, 2009, CLIN EXP RHEUMATOL, V27, pS63
- Lee KH, 1999, ARCH DERMATOL RES, V291, P374, DOI 10.1007/s004030050425
- Lee KH, 2003, ARTHRITIS RHEUM, V48, P2025, DOI 10.1002/art.11074
- Lopez-Alemany R, 2003, AM J HEMATOL, V72, P234, DOI 10.1002/ajh.10299
- MERONI PL, 1995, LUPUS, V4, P95, DOI 10.1177/096120339500400203
- Neves FS, 2007, CLIN RHEUMATOL, V26, P1263, DOI 10.1007/s10067-006-0484-y
- Neves FS, 2009, CLIN RHEUMATOL, V28, P543, DOI 10.1007/s10067-008-1081-z
- Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707
- Shin SJ, 2011, DIGEST DIS SCI, V56, P812, DOI 10.1007/s10620-010-1326-y
- Tunc R, 2002, J RHEUMATOL, V29, P2393
- Tursen U, 2003, INT J DERMATOL, V42, P346, DOI 10.1046/j.1365-4362.2003.01741.x
- Yurdakul Sebahattin, 2004, Current Opinion in Rheumatology, V16, P38
- Zouboulis CC, 1999, ANN MED INTERNE, V150, P488